The world of COVID-19 is always changing. Join Geoff Wall for a rapid fire of updates regarding famotidine, lockdowns, and ivermectin as evaluated for efficacy in COVID-19.

The GameChangers
The use of high-dose famotidine in the treatment of COVID-19 has demonstrated moderate safety, but questionable efficacy. Additionally, a recent meta-analysis examining the efficacy of lockdown on the spread of COVID-19 had several limitations that should be taken into consideration. 

Show Segments

00:00 – Introductions
01:56 – Famotidine in the Treatment of COVID-19
10:52 – Effects of Lockdown on COVID-19 Mortality 
18:26 – Ivermectin Treatment of COVID-19 in High-Risk Patients 
23:45 – Closing Remarks 

Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Redeem your CPE or CME credit here!

• Pharmacist members
• CME

Need a membership?

• Join for CPE Credit
• Join for CME Credit 

References and resources:

1. References and resources:
   1.     Oral Famotidine Versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blind, Data-Intense, Phase 2 Clinical Trial
   2.     A Literature Review and Meta-Analysis of the Effects of Lockdowns on COVID-19 Mortality. Pre-Publication.
   3.     Efficacy of Ivermectin Treatment on Disease Progression Among Adults with Mild to Moderate COVID-19 and Comorbidities

Continuing Education Information:

Learning Objectives:

1. 1. Describe the latest information on masks and other non-pharmacologic interventions to halt the spread of COVID-19
   2. Discuss the recent randomized controlled trial evaluating famotidine use in early COVID-19 positive patients

Dr. Wall is a member of the Janssen Speaker's Bureau.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-142-H01-P
Initial release date: 03/28/22
Expiration date: 03/28/2023

Follow CEimpact on Social Media:
LinkedIn
Instagram